Sponsored Content
Advertisement
Articles by Sponsored Content
Vincent Herrin, MD - University of Mississippi Medical Center Jackson, Mississippi
Advertisement
Latest Updated Articles
- POLIVY + BR: A Therapeutic Option Granted Accelerated Approval for R/R 3/L+DLBCL, NOS
Published: February 2nd 2020 | Updated:
- The Proposed Mechanism of Action of POLIVY for R/R DLBCL, NOS
Published: February 1st 2020 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Patient Case #2: Newly Diagnosed Stage 3B NSCLC
2
Remaining Unmet Needs in Biomarker Testing in Early-stage NSCLC
3
Multi-Trial Analysis Reveals Disconnect Between PFS and OS in Ovarian Cancer
4
Nogapendekin Alfa Inbakicept Shows Promise in Checkpoint-Refractory NSCLC
5